Table 3.

Baseline Characteristics of the Aspirin Group (n=502) According to the Presence of High or Low RPR

	High RPR (n=128)	Low RPR (n=374)	P*
Age, y, mean (range)	61.9 (44.9–80.3)	62.1 (36.4–80.8)	0.85
Sex, female, n (%)	31 (24.2)	81 (21.7)	0.55
Race, white, n (%)	119 (93.0)	364 (97.3)	0.07
Cardiovascular risk factors, n (%)
Current smoking	31 (24.2)	77 (20.6)	0.39
History of hypertension	63 (49.2)	209 (55.9)	0.19
Diabetes mellitus	29 (22.7)	76 (20.3)	0.58
Previous myocardial infarction	60 (46.9)	149 (39.8)	0.16
Intermittent claudication	5 (3.9)	24 (6.4)	0.29
Previous percutaneous coronary intervention	96 (75.0)	281 (75.1)	0.98
Previous coronary artery bypass grafting	26 (20.3)	77 (20.6)	0.95
Body mass index, kg/m2, median (25th, 75th percentiles)	26.9 (25.4, 29.3)	27.4 (24.9, 30.3)	0.52
Total cholesterol, mmol/L, mean±SD	4.46±0.89	4.60±0.99	0.14
High-density lipoprotein cholesterol, mmol/L, mean±SD	1.31±0.37	1.34±0.45	0.55
Low-density lipoprotein cholesterol, mmol/L, mean±SD	2.45±0.76	2.57±0.86	0.18
Triglycerides, mmol/L, median (25th, 75th percentiles)	1.32 (0.95, 1.90)	1.39 (0.93, 1.89)	0.61
Platelet count, ×109/L, median (25th, 75th percentiles)	231 (203, 273)	224 (193, 264)	0.05
Mean platelet volume, fL, mean±SD	10.99±0.85	10.87±0.94	0.21
C-reactive protein, mg/L, median (25th, 75th percentiles)	1.85 (1.1, 3.4)	1.90 (0.9, 3.4)	0.33
vWF, %, median (25th, 75th percentiles)	125 (98, 145)	100(79, 125)	<0.001
TxB2, ng/mL, mean (range)	2.9 (0.0–15.0)	2.6 (0.0–21.0)	0.32
Medication, n (%)
Statins	128 (100)	367 (98.1)	0.15
β-Blockers	99 (77.3)	284 (75.9)	0.86
Calcium channel blockers	26 (20.3)	97 (25.9)	0.21
Angiotensin-converting enzyme inhibitors	31 (24.2)	90 (24.1)	0.93
Angiotensin receptor blockers	30 (23.4)	100 (26.7)	0.48
Proton pump inhibitors	13 (10.2)	44 (11.8)	0.62

Values are given as n (%), mean±SD, mean (range), median (25th, 75th percentiles), or percentage, as indicated.

^*P for differences between groups.

Definitions as given in Table 1.